Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 01, 2015 8:42 PM ET

Pharmaceuticals

Company Overview of Lantheus Medical Imaging, Inc.

Company Overview

Lantheus Medical Imaging, Inc. develops, manufactures, and distributes diagnostic medical imaging products worldwide. The company offers imaging agents that assist in the diagnosis of heart, vascular, and other diseases using nuclear imaging, echocardiography, and magnetic resonance imaging (MRI) technologies. It offers DEFINITY, an injectable agent used during cardiac ultrasound or echocardiography for patients with suboptimal echocardiograms; TechneLite, a technetium generator used in nuclear medicine procedures; and Xenon Xe 133 Gas, a radiopharmaceutical gas that is used to assess pulmonary function. The company also provides Cardiolite, an injectable and technetium-labeled imaging agent...

331 Treble Cove Road

North Billerica, MA 01862

United States

Founded in 1956

524 Employees

Phone:

978-671-8001

Fax:

978-671-8860

Key Executives for Lantheus Medical Imaging, Inc.

Chief Executive Officer, President and Director
Age: 52
Chief Financial Officer
Age: 53
Chief Operating Officer
Age: 55
Vice President, General Counsel and Secretary
Age: 54
Chief Medical Officer
Age: 65
Compensation as of Fiscal Year 2015.

Lantheus Medical Imaging, Inc. Key Developments

Lantheus Medical Imaging, Inc. Enters into a Commercial Supply Agreement with Triad Isotopes, Inc

On June 19, 2015, Lantheus Medical Imaging, Inc. entered into a commercial supply agreement pursuant to which it will supply Triad Isotopes, Inc. with Xenon, Neurolite and Cardiolite products and, beginning in 2016, TechneLite generators. The agreement specifies pricing levels and requires Triad to purchase minimum volumes of certain products from the Company. The agreement expires on December 31, 2017 and may be terminated upon the occurrence of specified events, including a material breach by the other party and certain force majeure events.

Lantheus Medical Imaging, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Lantheus Medical Imaging, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company’s worldwide revenue totaled $74.8 million, representing a 2% increase as-reported and a 4% increase on a constant-currency basis over $73.3 million reported for the first quarter of 2014. The company reported quarterly GAAP-earnings profitability during the first quarter of 2015 with net income totaling $700,000, an improvement of nearly $2.0 million over a net loss of $1.3 million reported for the first quarter of 2014. Net income for the first quarter of 2015 included $3.6 million of non-cash costs associated with the company's previously announced campus consolidation initiative. The company's first quarter 2015 net income, as adjusted for the above items, totaled $4.3 million, an improvement of $5.6 million, compared to a net loss of $1.3 million for the first quarter of 2014. The company's first quarter Adjusted EBITDA, as defined in the GAAP to non-GAAP reconciliation provided later in this release, was $20.6 million, increasing by 29% from $16.0 million in the same quarter of the prior year. First quarter performance also reflects lower sales volumes but higher average selling prices and some mix shift in one customer channel, driven by a change in contract status. Net cash provided by operating activities was $15,157,000 compared to net cash used in operating activities of $15,000 a year ago. Capital expenditures were $3,498,000 compared to $1,482,000 a year ago.

Lantheus Medical Imaging, Inc., Q1 2015 Earnings Call, May 05, 2015

Lantheus Medical Imaging, Inc., Q1 2015 Earnings Call, May 05, 2015

Similar Private Companies By Industry

Company Name Region
Teva Pharmaceutical Finance Nv United States
Atlas U.S. Royalty, LLC United States
Io Therapeutics, Inc. United States
H3 Biomedicine Inc. United States
Med-Pharmex, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Lantheus Medical Imaging, Inc., please visit www.lantheus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.